{"disease":{"id":"pneumococcal-infection","name":"pneumococcal infection"},"drugs":{"marketed":[{"drug_id":"benzylpenicillin","indication_name":"Upper Respiratory Pneumococcal Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with HIV infection.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of pneumococcal meningitis in children 2 years of age or older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"penicillin","indication_name":"Upper Respiratory Pneumococcal Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenoxymethylpenicillin","indication_name":"Upper Respiratory Pneumococcal Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phenoxymethylpenicillin","company_name":"Katarina Hedin","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":28,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04664569","title":"National Bacterial Meningitis Study","phase":"","overall_status":"RECRUITING","enrollment_count":8230,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT04841369","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3420,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT04945681","title":"Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2882,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT05425732","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2663,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03692871","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2409,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03950856","title":"Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2340,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00427895","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2141,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03489018","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2100,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT05477693","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05731115","title":"Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03893448","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03547167","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1515,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04664556","title":"Invasive Pneumococcal Disease Study","phase":"","overall_status":"RECRUITING","enrollment_count":1369,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT06838000","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03950622","title":"Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1205,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03615482","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04016714","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1191,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04031846","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1184,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01215188","title":"A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1152,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06822907","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1052,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT02987972","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1051,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05380193","title":"Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France","phase":"","overall_status":"COMPLETED","enrollment_count":1017,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03574389","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":936,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03620162","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01654263","title":"A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":884,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT06177912","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":882,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05158140","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":850,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04384107","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":694,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01513551","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":692,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02547649","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":690,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03480763","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":652,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03885934","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07017777","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT04989465","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT02201030","title":"Immunogenicity and Safety Study of NBP606 in Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":577,"lead_sponsor_name":"SK Chemicals Co., Ltd.","has_results":false},{"nct_id":"NCT04887948","title":"Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":570,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03550313","title":"Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":565,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03276754","title":"Immunization To Prevent Acute COPD Exacerbations","phase":"","overall_status":"TERMINATED","enrollment_count":530,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05696080","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":518,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03313050","title":"A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06608199","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Beijing Minhai Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT03552445","title":"Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Korea University Guro Hospital","has_results":false},{"nct_id":"NCT02927444","title":"Immunogenicity and Safety Study of NBP606 in Healthy Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"SK Chemicals Co., Ltd.","has_results":false},{"nct_id":"NCT03512288","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03313037","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03921424","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02225587","title":"Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05412030","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02037984","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02531373","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}